Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines.
about
Mechanism of memantine block of NMDA-activated channels in rat retinal ganglion cells: uncompetitive antagonismOpen channel block and alteration of N-methyl-D-aspartic acid receptor gating by an analog of phencyclidine.Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer7-Chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine S,S-dioxide (IDRA 21), a congener of aniracetam, potently abates pharmacologically induced cognitive impairments in patas monkeysRevisiting AMPA receptors as an antiepileptic drug targetMemantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapsesDiverse mechanisms of antiepileptic drugs in the development pipelineMolecular targets for antiepileptic drug developmentEffects of the non-NMDA antagonists NBQX and the 2,3-benzodiazepine GYKI 52466 on different seizure types in mice: comparison with diazepam and interactions with flumazenilInhibition by memantine of the development of persistent oral dyskinesias induced by long-term haloperidol treatment of ratsPharmacodynamics of memantine: an update.The low-affinity, use-dependent NMDA receptor antagonist AR-R 15896AR. An update of progress in stroke.Active NMDA glutamate receptors are expressed by mammalian osteoclasts.Remacemide: current status and clinical applications.Preparation and characterization of the 'research chemical' diphenidine, its pyrrolidine analogue, and their 2,2-diphenylethyl isomers.Protection from glutamate-induced excitotoxicity by memantineEffects of memantine on recombinant rat NMDA receptors expressed in HEK 293 cellsRetigabine.Mitochondria in neuroplasticity and neurological disorders.Analgesic Efficacy of Nephrostomy Tract inFiltration of Bupivacaine and Ketamine after Tubeless Percutaneous Nephrolithotomy: A Prospective Randomized TrialSynaptic plasticity in glutamatergic and GABAergic neurotransmission following chronic memantine treatment in an in vitro model of limbic epileptogenesis.The AMPA receptor as a therapeutic target: current perspectives and emerging possibilities.The role of memantine in the treatment of psychiatric disorders other than the dementias: a review of current preclinical and clinical evidence.Preemptive use of ketamine on post operative pain of appendectomy.Pre-incisional analgesia with intravenous or subcutaneous infiltration of ketamine reduces postoperative pain in patients after open cholecystectomy: a randomized, double-blind, placebo-controlled study.Pre-incisional epidural ketamine, morphine and bupivacaine combined with epidural and general anaesthesia provides pre-emptive analgesia for upper abdominal surgery.Ion channels involved in stroke.A comparison of intravenous NBQX and GYKI 53655 as AMPA antagonists in the rat spinal cord.Excitatory amino acids in neonatal brain: contributions to pathology and therapeutic strategies.Voltage-dependent interaction of open-channel blocking molecules with gating of NMDA receptors in rat cortical neurons.Interactions of 2,3-benzodiazepines and cyclothiazide at AMPA receptors: patch clamp recordings in cultured neurones and area CA1 in hippocampal slices.A method for calculating the gas volume proportions and inhalation temperature of inert gas mixtures allowing reaching normothermic or hypothermic target body temperature in the awake rat.Establishment of CHO cell lines expressing four N-methyl-D-aspartate receptor subtypes and characterization of a novel antagonist PPDC.Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons.Xenon-helium gas mixture at equimolar concentration of 37.5% protects against oxygen and glucose deprivation-induced injury and inhibits tissue plasminogen activator.YM90K, a selective-amino-3-hydroxy5-methyl-4-isoxazole propionate (AMPA) receptor antagonist, prevents induction of heat shock protein HSP -70 and hsp -70 mRNA in rat retrosplenial cortex by phencyclidine.A new pyrrolyl-quinoxalinedione series of non-NMDA glutamate receptor antagonists: pharmacological characterization and comparison with NBQX and valproate in the kindling model of epilepsy.Anticonvulsant, but not antiepileptic, action of valproate on audiogenic seizures in metaphit-treated rats.Identification of ion-channel modulators that protect against aminoglycoside-induced hair cell death.Therapeutics of Neurotransmitters in Alzheimer's Disease.
P2860
Q24530210-EC985DB4-5086-48B0-AB51-C9C5B26EDD64Q24537274-F242188D-D473-4E4E-827A-654BF9F3F039Q24542039-6CBFB7B3-91DD-46DC-8CAF-53FC13A2474AQ24561600-09C1EEC4-1017-464B-93FA-7ED931376537Q24611163-1BCFE2B3-04CA-4853-92C3-D422CE5D9AB5Q24619395-AE4D3542-024F-444E-8593-DF2CE8A59485Q24675330-F5F9B968-0F1F-4A15-8FD8-F3D036C16051Q24683346-10A3A79F-7D6E-42E5-B3A9-CD7BE29C93B8Q28368896-9292EA17-0414-450F-A382-E5ADEF9CCFA6Q28379282-1AD961D8-C4C5-47EA-8013-6F524A495351Q30490604-949FEC82-B657-4E93-9405-7F255EAD9388Q33834192-115FAA16-B604-4B7D-97D4-481B1C3825FDQ33865399-76DDA8B0-7055-4E2F-B695-4207B6253CE4Q34074824-A82A2018-A4CD-4F29-BF45-5942B65AD23FQ34430008-B923E59C-1994-41AC-9532-B15E810046A7Q34442727-42B7FB25-5A43-44B8-AAD5-8A92678B3E6EQ35884655-9834B321-068A-4CF7-AF86-8785F405E459Q36697501-E0AFD0D1-A796-4EBD-A29D-B66C93B51124Q37216404-13823FB8-C759-4D37-9F17-5A638DA5104DQ37246417-EE6B9FD7-172E-4292-86BB-B420D210F648Q37430885-1F1E88FD-0E5B-4BED-BE36-4D77BA183105Q37855933-C3EE2E4B-6090-4AF0-95A8-EC31F0659843Q38025454-F6F4022D-A1E4-4100-A850-449C043A9D08Q38395936-C556DDAC-7BBE-4BC5-B276-F935360EB42EQ39261436-CE682699-5F32-4594-A3FD-9D61BB1A5FD7Q39432822-89E04BDD-A30A-454E-B41F-6595CD25F7B2Q40408915-D35A42FC-41D6-49D2-895C-01722ADD5125Q41837218-48878964-164D-4F73-946C-0254456F8703Q42425801-B7E16014-6AE4-4651-B387-C64C3CBE00F1Q42637358-BAE1A405-BF60-40A8-BA55-F5D3472E4D18Q42703440-69DCB5F3-5A89-4D75-966D-8FAA8AE89BD6Q43733724-D887BB06-13AF-48FF-90F6-806C74A4F3A7Q43759793-BF5B58F3-6CA4-4155-BD25-ED2D12963CC4Q44870767-8D3F5B81-1F18-4E5F-9D7F-425226AB3FD5Q46928898-E83FA1CA-2682-4109-A70F-D343A1F5CCAEQ47686282-280D7C8D-AFC2-4634-917D-AACA486532CFQ48284517-1CAE8DE5-A86B-4265-81C4-A2D6F023598BQ48459209-68982690-94EE-404A-9AF1-4D69AA2690FAQ49190945-A20AACBB-D8F6-4B0C-9EA9-9CE526B2DFF0Q49672905-42A1E4B4-28F2-48C3-9F52-8CF12EA8D30F
P2860
Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines.
description
1993 nî lūn-bûn
@nan
1993 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
name
Therapeutic potential of excit ...... ckers and 2,3-benzodiazepines.
@ast
Therapeutic potential of excit ...... ckers and 2,3-benzodiazepines.
@en
Therapeutic potential of excit ...... ckers and 2,3-benzodiazepines.
@nl
type
label
Therapeutic potential of excit ...... ckers and 2,3-benzodiazepines.
@ast
Therapeutic potential of excit ...... ckers and 2,3-benzodiazepines.
@en
Therapeutic potential of excit ...... ckers and 2,3-benzodiazepines.
@nl
prefLabel
Therapeutic potential of excit ...... ckers and 2,3-benzodiazepines.
@ast
Therapeutic potential of excit ...... ckers and 2,3-benzodiazepines.
@en
Therapeutic potential of excit ...... ckers and 2,3-benzodiazepines.
@nl
P1476
Therapeutic potential of excit ...... ckers and 2,3-benzodiazepines.
@en
P2093
Rogawski MA
P304
P356
10.1016/0165-6147(93)90005-5
P577
1993-09-01T00:00:00Z